Companies › RNA

ATRIUM THERAPEUTICS INC (RNA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002093101 · EDGAR filings · Updated 2026-07-27

ATRIUM THERAPEUTICS INC (RNA) has reported institutional ownership of 86.6%, with 160 institutional managers holding positions valued at $198.2M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Filings this week (1)

• 2026-07-27 — SCHEDULE 13G/A filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-14 — Current report (8-K) filed
• 2026-05-15 — SCHEDULE 13G filed
• 2026-05-14 — Quarterly report (10-Q) filed
• 2026-05-14 — Current report (8-K) filed
• 2026-04-27 — SCHEDULE 13G filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ATRIUM THERAPEUTICS INC has 160 institutional holders and institutional ownership of 86.6%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 11 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

KEROS THERAPEUTICS INC (KROS) · OPUS GENETICS INC (IRD) · OCUGEN INC COM (OCGN) · CONTEXT THERAPEUTICS INC (CNTX) · INHIBIKASE THERAPEUTICS INC (IKT) · ALECTOR INC (ALEC)